thoughts on these estimates, before EPS results? NASDAQ:CSX, NYSE:RHI, NASDAQ:NVEC, NASDAQ:BCLI

0
45

CSX EARNINGS ESTIMATES AND ACTUALS BY QUARTER
EARNINGS ESTIMATES AND ACUTALS BY QUARTER CHART DESCRIPTION (NASDAQ:CSX)

CSX last released its quarterly earnings results on October 19th, 2021. The transportation company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.05. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.06 billion. Its revenue was up 24.3% compared to the same quarter last year. CSX has generated $1.22 earnings per share over the last year ($1.48 diluted earnings per share) and currently has a price-to-earnings ratio of 23.9. Earnings for CSX are expected to grow by 11.92% in the coming year, from $1.51 to $1.69 per share. CSX has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, January 20th, 2022 based off prior year’s report dates.

IS CSX A BUY RIGHT NOW? (NASDAQ:CSX)

19 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for CSX in the last year. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” CSX stock.
CSX

ROBERT HALF INTERNATIONAL EARNINGS ESTIMATES AND ACTUALS BY QUARTER
EARNINGS ESTIMATES AND ACUTALS BY QUARTER CHART DESCRIPTION (NYSE:RHI)

Robert Half International last announced its quarterly earnings data on October 21st, 2021. The business services provider reported $1.53 EPS for the quarter, beating the consensus estimate of $1.40 by $0.13. Robert Half International has generated $2.70 earnings per share over the last year ($3.82 diluted earnings per share) and currently has a price-to-earnings ratio of 29.5. Earnings for Robert Half International are expected to grow by 1.79% in the coming year, from $5.02 to $5.11 per share. Robert Half International has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, January 27th, 2022 based off prior year’s report dates.

IS ROBERT HALF INTERNATIONAL A BUY RIGHT NOW? (NYSE:RHI)

9 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Robert Half International in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Robert Half International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RHI, but not buy additional shares or sell existing shares.
Robert Half International

NVE EARNINGS ESTIMATES AND ACTUALS BY QUARTER
EARNINGS ESTIMATES AND ACUTALS BY QUARTER CHART DESCRIPTION (NASDAQ:NVEC)

NVE last released its quarterly earnings results on July 21st, 2021. The semiconductor company reported $0.74 EPS for the quarter. The company earned $7.15 million during the quarter. NVE has generated $0.00 earnings per share over the last year ($2.66 diluted earnings per share) and currently has a price-to-earnings ratio of 25.5. NVE has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, January 19th, 2022 based off prior year’s report dates.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN NVE? (NASDAQ:NVEC)

Wall Street analysts have given NVE a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NVE wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

BRAINSTORM CELL THERAPEUTICS EARNINGS ESTIMATES AND ACTUALS BY QUARTER
EARNINGS ESTIMATES AND ACUTALS BY QUARTER CHART DESCRIPTION (NASDAQ:BCLI)

Brainstorm Cell Therapeutics last issued its quarterly earnings data on August 5th, 2021. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.07. Brainstorm Cell Therapeutics has generated ($1.07) earnings per share over the last year (($0.87) diluted earnings per share). Earnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.74) to ($1.01) per share. Brainstorm Cell Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, October 25th, 2021 based off prior year’s report dates.

IS BRAINSTORM CELL THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:BCLI)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Brainstorm Cell Therapeutics stock.
Brainstorm Cell Therapeutics